Skip to main content Skip to page footer

Welcome to ITCC-P4

Paediatric Preclinical Proof of Concept Platform

The Innovative Therapies for Children with Cancer Paediatric Preclinical Proof-of-concept Platform (ITCC-P4) is a non-profit initiative fighting for a childhood without cancer. 

At ITCC-P4, we pursue our vision by accelerating anti-cancer drug development through prioritization of the most relevant therapeutic assets for clinical development in children and adolescents with cancer.

ITCC-P4 therefore provides the world’s largest repertoire of freshly patient-derived models of paediatric tumours, available at one place, supported by a comprehensive dataset of corresponding molecular and pharmacological characterization. Complementary to long-lasting CRO experience in conducting preclinical testing experiments, we provide access to scientific preclinical expertise through a broad panel of highly diverse, internationally known, entity-specific experts.

Our combination of services is a unique and comprehensive answer to a double need, shared by public and private researchers:

  • Understand the underlying mechanisms of cancer and identify innovative treatment options for young patients.
  • Screen and assess molecules efficiently, helping to address regulatory bodies’ requests.

We act as a proactive, solution-oriented partner fully committed to efficient and effective evaluation of your assets, by designing, conducting, analysing and evaluating the experiments which best fit your purpose.

We believe that our non-profit initiative will contribute to a rapid and efficacious science-driven translation of innovative treatment approaches into clinically available therapeutics and rapid patient benefit.

Learn more about our offer, about us and get in touch to join our P4 community!

News

Every child with cancer deserves access to effective treatments. This Childhood…

The main publication from the ITCC-P4 consortium showcases a collaborative…

ITCC-P4 has submitted a joint response to EMA’s public consultation on…